Sugi Predict

Sugi Predict / Targets / AKR1C2

AKR1C2

Aldo-keto reductase family 1 member C2 · P52895 · AKR1C2 on Sugi Atlas →

113,527 patent compounds predicted against AKR1C2, 62,914 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL156023 SCHEMBL156023 0.64 17/20
SCHEMBL134150 SCHEMBL134150 0.65 13/20
Flurbiprofen Flurbiprofen (SCHEMBL2248) 1.00 11/20
Naproxen Naproxen (SCHEMBL3046) 1.00 11/20
Tarenflurbil Tarenflurbil (SCHEMBL26131) 1.00 11/20
Naproxen Naproxen (SCHEMBL42434) 1.00 11/20
Naproxen Naproxen (SCHEMBL145769) 1.00 11/20
Flurbiprofen Flurbiprofen (SCHEMBL26130) 0.97 11/20
Naproxen Naproxen (SCHEMBL7362) 0.97 11/20
SCHEMBL112764 SCHEMBL112764 0.59 10/20
SCHEMBL147211 SCHEMBL147211 0.54 10/20
SCHEMBL121984 SCHEMBL121984 0.54 9/20
SCHEMBL112627 SCHEMBL112627 0.50 9/20
SCHEMBL151193 SCHEMBL151193 0.52 8/20
SCHEMBL6766 SCHEMBL6766 0.50 8/20
SCHEMBL59197 SCHEMBL59197 0.68 7/20
Cinmetacin Cinmetacin (SCHEMBL25138) 0.63 7/20
Cinmetacin Cinmetacin (SCHEMBL25139) 0.63 7/20
SCHEMBL147187 SCHEMBL147187 0.63 7/20
SCHEMBL120025 SCHEMBL120025 0.46 7/20

Clinical trials — most relevant to AKR1C2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The Role of 5-alpha Reductase in Mediating Testosterone Actions PHASE4COMPLETED
Blood Pressure Regulation - Role of Potassium PHASE4COMPLETED
Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer PHASE3COMPLETED
Toxicity and Efficacy Evaluation of Topical Minoxidil in Acne Vulgaris PHASE1/PHASE2UNKNOWN
Acetylcarnitine and Insulin Sensitivity PHASE2COMPLETED
PR104 in Treating Patients With Refractory/Relapsed Acute Leukemia PHASE1/PHASE2UNKNOWN
Biomarkers in Bone Marrow and Blood Samples From Patients With Prostate Cancer Treated With Ketoconazole nanWITHDRAWN
Tissue Predictors of Abiraterone Benefit nanCOMPLETED
Adrenoleukodystrophy National Registry Study nanRECRUITING
ALDH2 Genetic Testing in East Asian Community nanNOT_YET_RECRUITING
5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy nanRECRUITING
Gene Expression, Metabolomic, Microbiome, and Calcium Metabolism in Response to Varied Vitamin D Dosages nanCOMPLETED
Gene Polymorphisms Influencing Steroid Synthesis and Action nanWITHDRAWN
Exercise Capacity, Physical Fitness, and Physical Activity Levels in Children With CAH nanCOMPLETED
EndoNAFLD: Relationship Between Fatty Liver Disease and Cardiovascular Diseases nanCOMPLETED
Influence of WNT4 VEZT FSHB and SIRT1 SNPs in Endometriosis: a Case Control Study of the Sardinian Population nanUNKNOWN
Ataxia-telangiectasia: Treating Mitochondrial Dysfunction With Nicotinamide Riboside nanUNKNOWN
A Study of Genetic Influence on LDL Hyper-responsiveness in Patients Following a Ketogenic Diet nanRECRUITING
Pharmacogenetic Determinants Of Treatment Response In Children nanRECRUITING
Final Height in Patients With CAH nanUNKNOWN
Environmental and Biological Monitoring Pilot Study for Polycyclic Aromatic Hydrocarbons in Linxian, China nanCOMPLETED
The Clinical and Economic Impact of Pharmacogenomic Testing of Warfarin Therapy in Typical Community Practice Settings nanCOMPLETED
Biomarkers in the Etiology of Idiopathic Intracranial Hypertension nanUNKNOWN
Tamoxifen Pharmacogenetics in Asian Breast Cancer Women nanUNKNOWN
Androgens and NAFLD Longitudinal Cohort Study nanRECRUITING
Pharmacogenetics of Alcohol: Treatment Implications nanCOMPLETED
Individualized Antiretroviral Therapy nanCOMPLETED
Evaluation of Hydroxymethylbutyrate Supplementation in Lung Transplant Candidates Receiving Pulmonary Rehabilitation nanCOMPLETED
Mutation Analysis of 17βhydroxysteroid Dehydrogenase 3 Deficiency nanUNKNOWN
Genetic, Dietary and Environmental Influences on Vitamin D Metabolism nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a AKR1C2 binder may also engage these)

ProteinNameSimilarity
AKR1C1 Aldo-keto reductase family 1 member C1 1.000 landscape →
AKR1C3 Aldo-keto reductase family 1 member C3 1.000 landscape →
Q5REQ0 — 1.000 Q5REQ0 →
Q5R7C9 — 1.000 Q5R7C9 →
Q95JH6 — 1.000 Q95JH6 →
Q6W8P9 — 1.000 Q6W8P9 →
Q95JH7 — 1.000 Q95JH7 →
Q1XAA8 — 1.000 Q1XAA8 →
P05980 — 0.996 P05980 →
Q95JH5 — 0.996 Q95JH5 →
AKR1C4 Aldo-keto reductase family 1 member C4 0.995 landscape →
P80508 — 0.995 P80508 →
P52898 — 0.995 P52898 →
Q95JH4 — 0.991 Q95JH4 →
P52897 — 0.990 P52897 →
P70694 — 0.986 P70694 →
D3ZF77 — 0.980 D3ZF77 →
Q91WR5 — 0.965 Q91WR5 →
Q5T2L2 — 0.959 Q5T2L2 →
Q6AYQ2 — 0.952 Q6AYQ2 →
Q8K023 — 0.949 Q8K023 →
P27119 — 0.942 P27119 →
P27118 — 0.942 P27118 →
Q9PTM4 — 0.941 Q9PTM4 →
P51652 — 0.941 P51652 →
P47727 — 0.940 P47727 →
P27117 — 0.940 P27117 →
B2GV72 — 0.938 B2GV72 →
Q6P8M1 — 0.938 Q6P8M1 →
P23457 — 0.938 P23457 →